Curis Highlights Publication Of Manuscript In Peer-Reviewed Journal ‘Gastroenterology’ On Role Of Protein Kinase IRAK4 In Pancreatic Ductal Adenocarcinoma And Preclinical Efficacy Of Co.’s Emavusertib In Combo With Checkpoint Immunotherapy
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a manuscript has been published in the peer-reviewed journal